BioCryst to Report Second Quarter 2024 Financial Results on August 5

Group 1 - BioCryst Pharmaceuticals will report its second quarter 2024 financial results on August 5, 2024 [1] - The management will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the financial results and provide a corporate update [1] - The live call can be accessed by domestic and international callers through specific dialing numbers [1] Group 2 - BioCryst Pharmaceuticals is a global biotechnology company focused on improving the lives of individuals with complement-mediated and other rare diseases [2] - The company utilizes structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics [2] - BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of therapies [2]